The FDA just made the presbyopia market a bit more crowded. On Wednesday, regulators approved Tenpoint Therapeutics' Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, marking the first dual-agent eye drop for treating presbyopia in adults. That's the gradual loss of near vision that sneaks up on most people around age 45—reading menus suddenly requires arm's length—and it affects roughly two billion people worldwide and 128 million in the U.S. alone.
Yuvezzi, previously known as Brimochol PF, is expected to hit pharmacy shelves broadly in the second quarter of 2026. For LENZ Therapeutics (LENZ), which scored its own presbyopia approval just months ago, the news wasn't exactly welcome. Shares dropped about 9% following the announcement.
Recent Competition in an Aging Market
The timing is notable because LENZ only got its FDA green light in August 2025 for VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved for presbyopia. So we're talking about a market that went from zero FDA-approved treatments to two in less than a year. That's the kind of rapid-fire approval sequence that makes investors nervous about market share.
Why Analysts Think the Selloff Misses the Mark
William Blair isn't buying the panic. In a Thursday note, the firm called the LENZ stock decline "an overreaction given this approval was expected, and we believe VIZZ still has a best-in-class profile."
Analyst Lachlan Hanbury-Brown laid out the case for why VIZZ maintains an edge. The drug has demonstrated greater efficacy with faster onset and longer durability across a broader patient population—advantages that show up clearly in the respective product labels. Those labels also reveal some meaningful mechanistic differences, particularly VIZZ's pupil selectivity, which appears to give it a cleaner safety profile.
Here's where it gets interesting: Yuvezzi's label includes risks that don't appear in VIZZ's documentation, notably the potential for exacerbating syndromes linked to vascular insufficiency and possible drug-drug interactions. Whether eye care professionals will view these label distinctions as clinically significant in practice remains an open question, Hanbury-Brown noted. But William Blair sees them as giving LENZ's sales team additional differentiation points beyond pure efficacy numbers.
Execution Matters More Than Competition
While investors fret about competitive dynamics, LENZ is focused on something more fundamental: actually getting doctors to prescribe VIZZ and patients to request it. The company made solid progress building awareness among eye care professionals during the fourth quarter, according to William Blair, which set the stage for its recent direct-to-consumer advertising push. That campaign should start translating awareness into demand over the coming quarters.
"We continue to believe VIZZ holds blockbuster potential and rate shares Outperform," Hanbury-Brown wrote.
As for the stock itself, LENZ shares were trading down 8.89% at $16.20 on Friday, hovering near the 52-week low of $14.43. That's a steep drop for a company that just launched what analysts believe could be a blockbuster product in a massive, underserved market. Sometimes Mr. Market overreacts to competition before anyone's actually competed.
